Topical becocalcidiol has shown promise in the treatment of patients with chronic plaque psoriasis

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1606, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efalizumab [Raptiva] will be available fully funded to patients in Australia for the treatment of severe chronic plaque psoriasis from 1 April 2006

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 498, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

The small-molecule inhibitor of survivin, YM 155, has shown promise for the treatment of solid tumours and lymphoma

Inpharma, Vol. 1, Iss. 1659, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

The Vx 001 [TERT572Y] vaccine has shown promise in the treatment of advanced non-small-cell lung cancer

Inpharma, Vol. 1, Iss. 1598, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Merck KGaA's cilengitide, a vitronectin inhibitor designed to inhibit angiogenesis, has shown promise as a treatment for recurrent glioblastoma.

Inpharma, Vol. 1, Iss. 1666, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Topical treatment of psoriasis

By Laws Philip M Young Helen S

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 1999-2009

Informa Healthcare

Access to resources Recommend Favorite